Abstract 70P
Background
Recently, the intratumor mycobiome has been characterized in 17,401 cancer patients, covering 35 cancer types from The Cancer Genome Atlas ( Narunsky-Haziza et al., 2022 ), revealing a previously overlooked aspect of cancer research. Moreover, Recent study showed that race is a key determinant of the human intratumor microbiome. We aimed to better understand the effects of patients’ demographic factors (age, sex, and race) on the intratumor mycobiome composition.
Methods
We analyzed the Narunsky-Haziza et al. de-contaminated and normalized intratumor fungal abundance data for 11 cancer types and 224 fungal species. We performed a systematic characterization of the tumor mycobiome across different cancer types using a propensity score algorithm, adjusting for the potential confounding factors of histological type and tumor stage.
Results
Fungus species abundances differed significantly between races in all cancer types. For example, in breast cancer, we identified 42 significantly differentially abundant fungal species in European vs. Asian, 45 species in European vs. African, and 56 in Asian vs. African. Notably, 19 fungal species Talaromyces marneffei, Scheffersomyces stipites, Debaryomyces fabryi, Lachancea lanzarotensis, Ogataea polymorpha, Tetrapisispora blattae, Fusarium proliferatum, Kazachstania Africana, Torulaspora delbrueckii, Naumovozyma castellii, Wickerhamomyces anomalus, Yamadazyma tenuis, Naumovozyma dairenensis, Sugiyamaella lignohabitans, Clavispora lusitaniae, Candida tropicalis, Vanderwaltozyma polyspora, Meyerozyma guilliermondii, Lachancea thermotolerans – had significantly different abundances in all three race comparisons. Moreover, regarding age (>65) and sex, only 5 fungal species abundance in stomach adenocarcinoma varied significantly for age and Malassezia sympodialis differed significantly with respect to sex. In thyroid carcinoma, 3 species varied by age and Cordyceps militaris for sex.
Conclusions
Our research reveals that the composition of the fungal community within tumors varies significantly across races, underscoring the importance of accounting for this demographic factor when conducting fungal-related analysis and clinical trials involving microbiota modulation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Edmond J. Safra Bioinformatics Center in Tel-Aviv University.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4P - Spatially resolved transcriptome elucidates bidirectional tertiary lymphoid structure interacts with tumor microenvironment of non-small cell lung cancer
Presenter: Xin Zhao
Session: Poster session 09
5P - Tertiary lymphoid structures (TLS) presence and stromal blood vessels heterogeneity differentially influence recurrence, lymphovascular, and perineural invasion in breast cancer molecular subtypes
Presenter: Andrei Cosma
Session: Poster session 09
6P - Combined single-cell and spatially resolved mapping of the human lymph node ecosystem reveals fundamental principles of lymphoma tissue organization
Presenter: Daniel Hübschmann
Session: Poster session 09
7P - Engineered salmonella blocks cancer metastasis by activating NK cells in an IFN-γ-dependent manner
Presenter: JIANDONG HUANG
Session: Poster session 09
8P - Modulating tumor microenvironment using a VEGF active immunotherapeutic approach in gastrointestinal tumors: Beyond angiogenesis modulation
Presenter: Mónica Bequet-Romero
Session: Poster session 09
9P - Identification of a μCT-based radiomic signature of CD8+ tumour infiltrating lymphocytes in an orthotopic murine model
Presenter: Giulia Mazzaschi
Session: Poster session 09
10P - Cancer cells induce intracellular gap formation in sinusoidal endothelial cells to produce liver metastasis through pro-inflammatory paracrine mechanisms
Presenter: Hoang Truong
Session: Poster session 09
11P - Targeting stromal cells to reverse immune suppression in triple-negative breast cancer
Presenter: Julia Chen
Session: Poster session 09
12P - Immuno-suppressive role of tumour-derived GDF-15 on myeloid cells
Presenter: Christine Schuberth-Wagner
Session: Poster session 09
13P - Disrupting the immunosuppressive tumor microenvironment using genetically engineered macrophages for triple-negative breast cancer therapy
Presenter: Sabrina Traxel
Session: Poster session 09